2-azetidinone derivatives and their use as cholesterol...

Details 2-azetidinone derivatives and their use as cholesterol... 2-azetidinone derivatives and their use as cholesterol...

2011-01-04

2011-01-04

Berch, Mark L (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C540S360000, C548S230000, C549S375000

Reexamination Certificate

active

07863265

ABSTRACT:
Compounds of formula (I) (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.

REFERENCES:
patent: 5633246 (1997-05-01), McKittrick et al.
patent: 5661145 (1997-08-01), Davis
patent: 5744467 (1998-04-01), McKittrick et al.
patent: 7235543 (2007-06-01), Burnett et al.
patent: 7368562 (2008-05-01), Burnett et al.
patent: 7470678 (2008-12-01), Starke et al.
patent: 2003/0119428 (2003-06-01), Davis et al.
patent: 2003/0119757 (2003-06-01), Davis
patent: 2004/0018060 (2004-01-01), Knezek et al.
patent: 2004/0018061 (2004-01-01), Jansson
patent: 2004/0254369 (2004-12-01), Framroze
patent: 2005/0096307 (2005-05-01), Graziano
patent: 2005/0267049 (2005-12-01), Goulet et al.
patent: 2006/0046996 (2006-03-01), Aoki et al.
patent: 2006/0069080 (2006-03-01), Veltri
patent: 2007/0049748 (2007-03-01), Uppala et al.
patent: 2007/0078098 (2007-04-01), DeVita et al.
patent: 2007/0129540 (2007-06-01), Framroze
patent: 2007/0142304 (2007-06-01), Alenfalk et al.
patent: 2007/0155674 (2007-07-01), Burnett et al.
patent: 2007/0155675 (2007-07-01), Burnett et al.
patent: 2008/0064676 (2008-03-01), Alenfalk et al.
patent: 2008/0070890 (2008-03-01), Burnett et al.
patent: 2009/0069285 (2009-03-01), Lemurell et al.
patent: 2010/0048529 (2010-02-01), Dahlstrom et al.
patent: 2010/0048530 (2010-02-01), Dahlstrom et al.
patent: 2010/0099657 (2010-04-01), Alenfalk et al.
patent: 2010/0125059 (2010-05-01), Nakano et al.
patent: 2010/0137273 (2010-06-01), Alenfalk et al.
patent: 2010/0152156 (2010-06-01), Dahlstrom et al.
patent: 2010/0168075 (2010-07-01), Dahlstrom et al.
patent: 1413331 (2001-09-01), None
patent: 0792264 (2002-02-01), None
patent: 1362855 (2003-11-01), None
patent: 2004081002 (1996-05-01), None
patent: 03026643 (2003-04-01), None
patent: 2004005247 (2004-01-01), None
patent: 2004043456 (2004-05-01), None
patent: 2004043457 (2004-05-01), None
patent: 2004099132 (2004-11-01), None
patent: 2004107958 (2004-12-01), None
patent: 2005000353 (2005-01-01), None
patent: 2005021495 (2005-03-01), None
patent: 2005021497 (2005-03-01), None
patent: 2005042692 (2005-05-01), None
patent: 2005044256 (2005-05-01), None
patent: 2005047248 (2005-05-01), None
patent: 2005049592 (2005-06-01), None
patent: 2005058316 (2005-06-01), None
patent: 2005033100 (2005-07-01), None
patent: 2005061451 (2005-07-01), None
patent: 2005061452 (2005-07-01), None
patent: 2005062824 (2005-07-01), None
patent: 2005062897 (2005-07-01), None
patent: 2005066120 (2005-07-01), None
patent: 2005067903 (2005-07-01), None
patent: 2005069900 (2005-08-01), None
patent: 2005113495 (2005-12-01), None
patent: 2005113496 (2005-12-01), None
patent: 2006017257 (2006-02-01), None
patent: 2006060808 (2006-06-01), None
patent: 2006068990 (2006-06-01), None
patent: 2006072957 (2006-07-01), None
patent: 2006086562 (2006-08-01), None
patent: 2006102674 (2006-09-01), None
patent: 2006107936 (2006-10-01), None
patent: 2006116499 (2006-11-01), None
patent: 2006121861 (2006-11-01), None
patent: 2006122186 (2006-11-01), None
patent: 2006122216 (2006-11-01), None
patent: 2006124713 (2006-11-01), None
patent: 2006127893 (2006-11-01), None
patent: 2006134604 (2006-12-01), None
patent: 2006137080 (2006-12-01), None
patent: 2006137782 (2006-12-01), None
patent: 2006137792 (2006-12-01), None
patent: 2006137793 (2006-12-01), None
patent: 2006137794 (2006-12-01), None
patent: 2006137795 (2006-12-01), None
patent: 2006137796 (2006-12-01), None
patent: 2006137797 (2006-12-01), None
patent: 2006138163 (2006-12-01), None
patent: 2007003365 (2007-01-01), None
patent: 2007008529 (2007-01-01), None
patent: 2007008541 (2007-01-01), None
patent: 2007015161 (2007-02-01), None
patent: 2007016643 (2007-02-01), None
patent: 2007017705 (2007-02-01), None
patent: 2007030721 (2007-03-01), None
patent: 2007058335 (2007-05-01), None
patent: 2007059871 (2007-05-01), None
patent: 2007072088 (2007-06-01), None
patent: 2007075702 (2007-07-01), None
Office Action dated May 3, 2010 received in copending U.S. Appl. No. 10/596,731.
Office Ation dated Jul. 15, 2009 received in copending U.S. Appl. No. 10/596,725.
Office Action dated Sep. 17, 2009 received in copending U.S. Appl. No. 10/596,731.
McKittrick, B.A., et al., “Synthesis of C3 Heteroatom-substituted Azetidinones that Display Potent Cholesterol Absorption Inhibitory Activity”, J. Med. Chem., 1998, 41:752-759.
Notice of allowance dated Jul. 31, 2008 for U.S. Appl. No. 10/519,897.
Office Action dated Feb. 28, 2008 for U.S. Appl. No. 10/519,897.
Notice of allowance dated Aug. 28, 2007 for U.S. Appl. No. 10/519,897.
Office Action dated May 1, 2007 for U.S. Appl. No. 10/519,897.
Ritter et al., “Heterocyclic ring scaffolds as small-molecule cholesterol absorption inhibitors,” Org Biomol Chem (2005) 3:3514-3523.
Clader et al., “2-Azetidinone Cholesterol Absorption Inhibitors: Structure-Activity Relationships on the HeterocyclicNucleus,” J. Med Chem (1996) 39:3684-3693.
McKittrick et al., Stereoselective synthesis and biological activity of cis azetidinones as cholesterol absorptioninhibitors, Bioorganic & Medicinal Chemistry Letters (1996) 6(16):1947-1950.
Burnett et al., “2-Azetidinones as Inhibitors of Cholesterol Absorption,” J. Med Chem (1994) 12:1733-1736.
Castaner et al., “Ezetimibe Hypolipidemic, Cholesterol absorption inhibitor,” Drugs of the Future (2000) 25(7):679-685.
Vaccaro et al., “Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: Enhanced potency by modification ofthe sugar,” Bioorganic & Medicinal Chemistry Letters (1998) 8:313-318.
Fu et al., “Process for preparing Ezetimibe intermediate by an acid enhanced chemo- and enantioselective CBScatalyzed ketone reduction,” Tetrahedron Letters (2003) 44:801-804.
Kirkup et al., “(I)-SCH 57939: synthesis and pharmacological properties of a potent, metabolically stable cholesterolabsorption inhibitor,” Bioorganic & Medicinal Chemistry Letters (1996) 6(17):2069-2072.
Rosenblum et al., “Discovery of 1-(4-fluorophenyl)-(3R)[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.,” J. Med Chem (1998) 41:973-980.
Wu et al., “A Novel One-Step Diastereo- and Enantioselective Formation of trans-Azetidinones and Its Application tothe Total Synthesis of Cholesterol Absorption Inhibitors,” J. Org. Chem (1999) 64:3714-3718.
Dugar et al., “Gamma-lactams and related compounds as cholesterol absorption inhibitors: homologs of the beta-lactam cholesterol absorption inhibitor SCH 48461,” Bioorganic & Medicinal Letters (1995) 5(24):2947-2952.
Mounsey et al., “Diet may slow progression of diabetic nephropathy,” The Journal of Family Practice (2003) 52(9):672-673.
Sobieszczyk et al., “Acute pulmonary embolism: don't ignore the platelet,” Circulation (2002) 106(14):1748-1749.
van Heek et al., “Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663,” Br. J. Pharmacol (2000) 129(8):1748-1754.
Yang et al., “Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes,”Circulation (2002) 105(16):1943-1948.
Zaks et al., Enzymatic glucuronidation of a novel cholesterol absorption inhibitor, Sch 58235, Appl BiochemBiotechnol. (1998) 73(2-3):205-214.
Clader “The discovery of ezetimibe: a view from outside the receptor,” J Med Chem (2004 47(1):1-9.
Altmann et al., “Niemann-pick C1 like 1 protein is critical for intestinal cholesterol absorption,” Science(2004) 303:1201-1204.
Carcia-Calvo et al., “The target of ezetimibe is Niemann-Pick C1-Like

Affiliated with

Also associated with

Rating

2-azetidinone derivatives and their use as cholesterol... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2-azetidinone derivatives and their use as cholesterol..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-azetidinone derivatives and their use as cholesterol... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2737912